Asian Conference on Clinical Pharmacy, Best Poster Presenter,Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched StudyHaruna Matsuzaki Masakazu Hatano Miko Iwata Shigeki Yamada
Taro Kishi Kenji Sakuma Masakazu Hatano Takenori Okumura Masaki Kato Hajime Baba Nakao Iwata
Neuropsychopharmacology reports 2024年2月
AIM: To update the major depressive disorder (MDD) treatment guidelines of the Japanese Society of Mood Disorders, we conducted a systematic review and pairwise meta-analysis of double-blind, randomized, placebo-controlled trials of available anti...
Journal of psychiatric research 167 132-138 2023年10月
The benefits of serotonin 3 receptor antagonists (5-HT3R-As) in obsessive-compulsive disorder (OCD) treatment remain unclear. Thus, this study aimed to perform a systematic review and a random-effects meta-analysis, including double-blind, randomi...
Miko Iwata Masakazu Hatano Kana Ito Haruna Matsuzaki Shigeki Yamada
Neuropsychiatric disease and treatment 19 2061-2068 2023年10月
PURPOSE: Several nationwide population-based studies have reported that patients with psychiatric disorders are at higher risk of developing chronic kidney disease, chronic liver disease, and metabolic syndrome than the general population; however...
BACKGROUND: Clozapine is the only antipsychotic medication with proven efficacy against treatment-resistant schizophrenia. This multicenter retrospective cohort study aimed to evaluate the impact of a delay in clozapine initiation on long-term out...
お知らせ・マニュアル
医学部